[go: up one dir, main page]

AR097172A1 - Composiciones vacunales bivalentes y su uso para la terapia de tumores - Google Patents

Composiciones vacunales bivalentes y su uso para la terapia de tumores

Info

Publication number
AR097172A1
AR097172A1 ARP140102872A ARP140102872A AR097172A1 AR 097172 A1 AR097172 A1 AR 097172A1 AR P140102872 A ARP140102872 A AR P140102872A AR P140102872 A ARP140102872 A AR P140102872A AR 097172 A1 AR097172 A1 AR 097172A1
Authority
AR
Argentina
Prior art keywords
vaccine compositions
tumor therapy
tumor
bivalent vaccine
vssp
Prior art date
Application number
ARP140102872A
Other languages
English (en)
Inventor
Snchez Ramrez Belinda
Yglesias Rivera Arianna
Gutirrez Prez Amelia
Gonzlez Surez Narjara
Original Assignee
Centro De Inmunología Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51453541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR097172(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro De Inmunología Molecular filed Critical Centro De Inmunología Molecular
Publication of AR097172A1 publication Critical patent/AR097172A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composiciones vacunales que combinan en igual proporción los dominios extracelulares de los receptores de factores de crecimiento Her1 y Her2 o fragmentos de estos y adicionalmente proteoliposomas de muy pequeña talla derivado de proteínas de la membrana externa de Neisseria meningitidis y el gangliósido GM3 (VSSP-GM3), que están destinadas a la administración subcutánea. Las composiciones descritas permiten inducir anticuerpos para el tratamiento de tumores malignos y presentan ventajas debido a que logran eliminar totalmente la masa tumoral y evitan la regresión del tumor a partir de la aparición de variantes resistentes.
ARP140102872A 2013-08-02 2014-07-31 Composiciones vacunales bivalentes y su uso para la terapia de tumores AR097172A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CUP2013000110A CU24299B1 (es) 2013-08-02 2013-08-02 Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico

Publications (1)

Publication Number Publication Date
AR097172A1 true AR097172A1 (es) 2016-02-24

Family

ID=51453541

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102872A AR097172A1 (es) 2013-08-02 2014-07-31 Composiciones vacunales bivalentes y su uso para la terapia de tumores

Country Status (24)

Country Link
US (2) US20160166667A1 (es)
EP (1) EP3028714B1 (es)
JP (1) JP6479002B2 (es)
KR (1) KR20160018665A (es)
CN (1) CN105407916A (es)
AR (1) AR097172A1 (es)
AU (1) AU2014298978B2 (es)
CA (1) CA2916552C (es)
CL (1) CL2015003706A1 (es)
CU (1) CU24299B1 (es)
EA (1) EA034194B1 (es)
ES (1) ES2894075T3 (es)
HK (1) HK1220141A1 (es)
IL (1) IL243879B (es)
MX (1) MX377537B (es)
MY (1) MY194889A (es)
PE (1) PE20160174A1 (es)
PH (1) PH12016500224A1 (es)
SG (1) SG11201600084WA (es)
TN (1) TN2015000557A1 (es)
TW (1) TWI554281B (es)
UA (1) UA116154C2 (es)
WO (1) WO2015014327A1 (es)
ZA (1) ZA201601328B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12019073B2 (en) 2017-03-15 2024-06-25 Centro De Inmunologia Molecular Method for the treatment of patients with carcinomas
EP3597214A1 (en) * 2017-03-15 2020-01-22 Centro de Inmunologia Molecular Method for the treatment of patients with carcinomas
CU24534B1 (es) * 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4306697A1 (de) * 1993-03-04 1994-09-08 Merck Patent Gmbh Mittel und Verfahren zur immunologischen Bestimmung von Diphenhydramin und dessen Metaboliten
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
EP2639299A1 (en) * 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase

Also Published As

Publication number Publication date
PE20160174A1 (es) 2016-04-20
AU2014298978A1 (en) 2016-02-25
CA2916552A1 (en) 2015-02-05
EA034194B1 (ru) 2020-01-16
ES2894075T3 (es) 2022-02-11
BR112016002174A2 (pt) 2017-08-01
WO2015014327A1 (es) 2015-02-05
EA201690309A1 (ru) 2016-06-30
MY194889A (en) 2022-12-21
AU2014298978B2 (en) 2019-05-23
EP3028714A1 (en) 2016-06-08
ZA201601328B (en) 2017-11-29
IL243879A0 (en) 2016-04-21
CU24299B1 (es) 2017-12-08
TW201521765A (zh) 2015-06-16
HK1220141A1 (zh) 2017-04-28
MX2016001459A (es) 2017-01-05
JP6479002B2 (ja) 2019-03-06
SG11201600084WA (en) 2016-02-26
NZ716579A (en) 2021-10-29
CA2916552C (en) 2020-03-31
US20160166667A1 (en) 2016-06-16
IL243879B (en) 2019-09-26
KR20160018665A (ko) 2016-02-17
CN105407916A (zh) 2016-03-16
EP3028714B1 (en) 2021-09-29
US20190275132A1 (en) 2019-09-12
TWI554281B (zh) 2016-10-21
TN2015000557A1 (en) 2017-04-06
JP2016525555A (ja) 2016-08-25
MX377537B (es) 2025-03-10
PH12016500224A1 (en) 2016-05-16
CL2015003706A1 (es) 2016-07-22
UA116154C2 (uk) 2018-02-12
CU20130110A7 (es) 2015-03-30

Similar Documents

Publication Publication Date Title
CY1123258T1 (el) Μεθοδος θεραπειας για τον καρκινο
CL2016002359A1 (es) Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco
MX2019008350A (es) Formulaciones de anticuerpos de her2 subcutáneas.
BR112016025035A2 (pt) imunoterapia contra diversos tumores hematológicos, como a leucemia mieloide aguda (aml)
CY1122483T1 (el) Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης
ECSP088753A (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
MX420412B (es) Plinabulina, composiciones que la comprenden y sus usos en el tratamiento de cáncer asociado con mutación del egfr.
PE20080663A1 (es) Terapia tumoral con una combinacion de anticuerpos anti-her2
WO2014168548A3 (en) Therapeutic delivery vesicles
EA201790404A1 (ru) Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
CR20160018A (es) Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc)
UA103202C2 (ru) Фармацевтическая композиция опухолеассоциированных пептидов и ее применение для лечения раковых заболеваний
BR112012030479A2 (pt) terapia aprimorada de câncer baseada em antígenos associados a tumor derivados de ciclina d1
MX392408B (es) Tratamiento de cáncer gástrico usando terapias de combinación que comprenden irinotecán liposómico oxaliplatino, 5-fluoruracilo (y leucovorina).
UA118354C2 (uk) Антитіло до рецептора колонієстимулювального фактора (кфс-1r)
EA201690388A1 (ru) Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов
AR097172A1 (es) Composiciones vacunales bivalentes y su uso para la terapia de tumores
EA201691385A1 (ru) Комбинированная терапия рака
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
CY1122042T1 (el) Συνθεση για χρηση στη θεραπεια του πονου που σχετιζεται με μεσοσπονδυλιο δισκο
EA201591902A1 (ru) Способы и композиции, использующие 4-амино-2-(2,6-диоксо-пиперидин-3-ил)изоиндолин-1,3-дион для лечения и контроля злокачественных опухолей центральной нервной системы
BR112015022010A2 (pt) Uso de sdf-1 para mitigar a formação de cicatrizes
CO2019003865A2 (es) Proteína terapéutica
MX385144B (es) Anticuerpo anti-integrina alfa v para el tratamiento de cáncer de próstata.
CY1117579T1 (el) Παραγωγα φαινυλιου-γουανiδiνης

Legal Events

Date Code Title Description
FB Suspension of granting procedure